Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZeneca's EBIT per Share for the
three
months ended in Mar. 2026 was €1.20.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €4.06.
During the past 12 months, the average EBIT per Share Growth Rate of AstraZeneca was 29.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 39.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for AstraZeneca's EBIT per Share or its related term are showing as below:
STU:ZEGA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.6 Med: 10.4 Max: 39
Current: 39
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AstraZeneca was 39.00% per year. The lowest was -41.60% per year. And the median was 10.40% per year.
STU:ZEGA's 3-Year EBIT Growth Rate is ranked better than 83.48% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs STU:ZEGA: 39.00
AstraZeneca's EBIT for the
three
months ended in Mar. 2026 was €3,726 Mil.
AstraZeneca (STU:ZEGA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
AstraZeneca EBIT per Share Related Terms
AstraZeneca EBIT per Share Historical Data
* Premium members only.
The historical data trend for AstraZeneca's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (STU:ZEGA) has a EBIT per Share of €4.06 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AstraZeneca and its competitors. According to the industry distribution chart, AstraZeneca ranks #134 out of 811 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is AstraZeneca's EBIT per Share too high?
AstraZeneca's current EBIT per Share is €4.06. Based on the distribution chart, AstraZeneca ranks #134 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #134 out of 811 companies for EBIT per Share. This places AstraZeneca in the top 17% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AstraZeneca and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current EBIT per Share is €4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current EBIT per Share of €4.06. The stock's GF Value™ is €84.84, compared to a current price of €78.00 — trading 8.1% below its estimated fair value. The current EBIT per Share is €4.06. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current EBIT per Share is €4.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (STU:ZEGA) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued.
The current stock price of €78.00 is trading 8.1% below its estimated GF Value™ of €84.84.
Key valuation signals for STU:ZEGA:
EBIT per Share: €4.06
GF Value™: €84.84 vs. price of €78.00 (8.1% below fair value)
No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score
Get the complete analysis for STU:ZEGA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZEGA has been successfully added to your 
